Author Archives: Administrator

2017/11/17 Reven News Press

Reven receives Patent Approval in Mexico.

2017/11/10 Reven News Press

Reven filed divisional patent in China.

2017/11/01 Reven News Press

Kelly Stanton hired as Reven’s Senior Quality Assurance Manager.

2017/09/12 Reven News Press

Reven selected an American Contract Research Organization (CRO) to help with all analytical studies.

2017/09/08 Reven News Press

Reven received approval for our Family Two 1st Divisional Patent.

2017/09/01 Reven News Press

Reven filed a Family One continuation patent.

2017/08/18 Reven News Press

Reven submits divisional patents in Canada and Mexico.

2017/07/24 Reven News Press

Reven receives approval in Canada for our Family Two Patent.

07/10/2017 Reven News Press

Reven selected an Australian Contract Manufacturing Organization (CMO) to supply drug product for Phase I Clinical Trial

2017/07/10 Reven News Press

Reven selected an Australian Contract Manufacturing Organization (CMO) to supply drug product for Phase I Clinical Trial.

07/03/2017 Reven News Press

Canadian Intellectual Property Office approved our Family Two patent in Canada

2017/07/03 Reven News Press

Canadian Intellectual Property Office approved our Family Two patent in Canada.

06/12/2017 Reven News Press

The US Patent and Trademark Office (USPTO) allowed Reven RJX Family One Child Patent, application # 14,550,677. This is our “method of treating” patent.

2017/06/12 Reven News Press

Joy Powell hired as Reven’s Senior Project Manager overseeing analytical and bioanalytical work.

2017/06/12 Reven News Press

Reven selected Linear Clinical Research as the Phase I research site in Australia.